Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens

Antiviral Therapy

Volumn 13, Issue 2, 2008, Pages 231-240

  Negredo, Eugenia ^a   Garrabou, Glória ^b,c   Puig, Jordi ^a   Lòpez, Soǹia ^b,c   Morén, Constanza ^b,c   Bellido, Rocio ^a   Ayen, Rafaela ^a   Cardellach, Francesc ^b,c   Miró, Óscar ^b,c   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CYTOCHROME C OXIDASE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; NEVIRAPINE; SUCCINATE DEHYDROGENASE (UBIQUINONE); TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOTOXICITY; DNA DAMAGE; DRUG DOSE REGIMEN; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LYMPHOCYTE COUNT; MALE; MITOCHONDRIAL TOXICITY; MITOCHONDRION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; WESTERN BLOTTING;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; MITOCHONDRIA; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 42149180678     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-422.
2. Cherry CL, Wesselingh SL. Nucleoside analogues and HIV: the combined cost to mitochondria. J Antimicrob Chemother 2003; 51:1091-1093.
3. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PR Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
4. Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase γ. J Biol Chem 2001; 276:23616-23623.
5. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
6. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
7. Galluzi L, Pinti M, Troiano L, et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 2005; 10:191-195.
8. Tomelleri G, Tonin P, Spadaro M, et al. AZT-induced mitochondrial myopathy. Ital J Neurol Sci 1992; 13:723-728.
9. Barile M, Valenti D, Quagliariello E, Passarella S. Mitochondria as cell targets of AZT (zidovudine). Gen Pharmacol 1998; 31:531-538.
10. Dalakas MC, Leon-Monzon ME, Bernardini I, Gahl WA, Jay CA. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 1994; 35:482-487.
11. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-2739.
12. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 2005; 65:413-432.
13. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-723.
14. López S, Negredo E, Garrabou G, et al. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retrov. 2006; 22:33-39.
15. + cell count decline in HIV-infected patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18:459-463.
16. + T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:569-575.
17. Ray AS, Olson L, Fridland A. Role of purine nucleoside Phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-1095.
18. Pruvost A, Negredo E, Benech H, et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs: analysis in HIV-infected patients. Antimicrob Agents Chemother 2005; 49:1907-1914.
19. Kearney BP, Damle B, Plummer A, et al. Pharmacokinetics evaluation of tenofovir DF and enteric-coated didanosine. Sixth International Congress on Drug Therapy in HIV Infection. 17-21 November 2002, Glasgow, UK. Abstract 186.
20. Pecora Fulco P, Kirian MA. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 2003; 37:1325-1328.
21. Martinez E, Milinkovic A, de Lazzari E, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364:65-67.
22. Blanchard JN, Wohlfeiler M, Canas A King K, Lonergan JT. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. Clin Infect Dis 2003; 37:e57-62.
23. Kearney BP, Isaacson E, Sayre I, Namini H, Cheng A. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. 10th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003, Boston, USA. Abstract 533.
24. Kaul S, Damle B, Bassi K, et al. Pharmacokinetic evaluation of reduced doses of didanosine enteric coated capsules (ddl-EC) in combination with tenofovir disoproxil fumarate (TDF) and food for a once-daily antiretroviral regimen. 4th International Workshop on Clinical Pharmacology of HIV Therapy. 27-29 March 2003, Cannes, France. Abstract 8.1.
25. Miro O, Lopez S, Pedrol E, Rodriguez-Santiago B, et al. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Ther 2003; 8:333-338.
26. Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228:35-51.
27. Miró O, Cardellach F, Barrientos A, Casademont J, Rötig A, Rustin P. Cytochrome c oxidase assay in minute amounts of human skeletal muscle using single wavelength spectrophotometers. J Neurosci Methods 1998; 80:107-111.
28. Miró O, López S, Rodríguez de la Concepción M, et al. Upregulatory mechanisms compensate for mitochondrial DNA depletion in asympthomatic individuals receiving stavudine plus didanosine. J Aquir Immune Defic Syndr 2004; 37:1550-1555.
29. Young B, Weidle PJ, Baker RK, et al. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons. AIDS Patient Care STDs 2006; 20:238-244.
30. Tung M-Y, Mandalia S, Bower M, Gazzard B, Nelson M. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily. HIV Medicine 2005; 6:151-154.
31. Galluzzi L, Pinti M, Troiano L, et al. Changes in mtRNA production in cells treated with nucleoside analogues. Antivir Ther 2005; 10:191-195.
32. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-820.
33. Miró O, López S, Martínez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Disease 2004; 39:710-716.
34. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
35. Mussini C, Pinti M, Bugarini R, et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 2005; 19:1627-1633.
36. Keiser P, Turner D, Ramillo O, Kvanli MB, Smith JW, Nassaret N. An open-label pilot study of the efficacy and tolerability of once daily didanosine versus twice-daily didanosine. Clin Infect Dis 1998; 27:400-401.
37. Hawkins T, Veikley W, St Claire RL, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39:406-411.
38. Miró Ò, López S, Martínez E, et al. Reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy. AIDS Res Hum Retroviruses 2003; 19:1027-1032.
39. Miró Ò, Pedrol E, Cebrian M, et al. Skeletal muscle studies in patients with HIV-related wasting syndrome. J Neurol Sci 1997; 150:153-159.
40. Milinkovic A, Martinez E, Lopez S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12:407-415.